Rigel Pharmaceuticals (RIGL) Free Cash Flow (2010 - 2026)
Rigel Pharmaceuticals' quarterly Free Cash Flow came in at $2.7 million in Q1 2026, up 405.15% year-on-year from $539442.5 in Q1 2025, and down 87.61% quarter-over-quarter from $22.0 million in Q4 2025.
Rigel Pharmaceuticals has reported Free Cash Flow for 17 years, with the latest figure at $2.7 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 405.15% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $79.3 million (up 122.93% YoY), and the FY2025 full-year result was $75.7 million, up 140.67% from the prior year.
- Free Cash Flow for Q1 2026 stood at $2.7 million, down from $22.0 million in the prior quarter.
- The five-year high for Free Cash Flow was $30.5 million in Q2 2025, with the low at -$25.9 million in Q1 2022.
- Average Free Cash Flow over 5 years is $1.8 million, with a median of -$893000.0 recorded in 2025.
- Year-over-year, Free Cash Flow sank 123.49% in 2022 and surged 10011.59% in 2025.
- Tracing RIGL's Free Cash Flow over 5 years: stood at -$22.0 million in 2022, then jumped by 71.61% to -$6.2 million in 2023, then jumped by 332.0% to $14.5 million in 2024, then soared by 51.91% to $22.0 million in 2025, then slumped by 87.61% to $2.7 million in 2026.
- The last three Free Cash Flow figures came in at $2.7 million (Q1 2026), $22.0 million (Q4 2025), and $24.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 2.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.73 Mn |
| Mar 31, 2026 | 2.73 Mn |
| Dec 31, 2025 | 21.99 Mn |
| Dec 31, 2025 | 21.99 Mn |
| Sep 30, 2025 | 24.03 Mn |
| Sep 30, 2025 | 24.03 Mn |
| Jun 30, 2025 | 30.54 Mn |
| Jun 30, 2025 | 30.54 Mn |
| Mar 31, 2025 | -893,000.00 |
| Mar 31, 2025 | -893,000.00 |
| Dec 31, 2024 | 14.48 Mn |
| Dec 31, 2024 | 14.48 Mn |
| Sep 30, 2024 | 21.68 Mn |
| Sep 30, 2024 | 21.68 Mn |
| Jun 30, 2024 | 302,000.00 |
| Jun 30, 2024 | 302,000.00 |
| Mar 31, 2024 | -5.01 Mn |
| Mar 31, 2024 | -5.01 Mn |
| Dec 31, 2023 | -6.24 Mn |
| Dec 31, 2023 | -6.24 Mn |
| Sep 30, 2023 | -1.36 Mn |
| Sep 30, 2023 | -1.36 Mn |
| Jun 30, 2023 | 5.93 Mn |
| Jun 30, 2023 | 5.93 Mn |
| Mar 31, 2023 | -4.07 Mn |
| Mar 31, 2023 | -4.07 Mn |
| Dec 31, 2022 | -21.98 Mn |
| Dec 31, 2022 | -21.98 Mn |
| Sep 30, 2022 | -13.49 Mn |
| Sep 30, 2022 | -13.49 Mn |
| Jun 30, 2022 | -12.88 Mn |
| Jun 30, 2022 | -12.88 Mn |
| Mar 31, 2022 | -25.86 Mn |
| Mar 31, 2022 | -25.86 Mn |
| Dec 31, 2021 | -19.07 Mn |
| Dec 31, 2021 | -19.07 Mn |
| Sep 30, 2021 | -10.47 Mn |
| Sep 30, 2021 | -10.47 Mn |
| Jun 30, 2021 | 54.81 Mn |
| Jun 30, 2021 | 54.81 Mn |
| Mar 31, 2021 | -20.03 Mn |
| Mar 31, 2021 | -20.03 Mn |
| Dec 31, 2020 | -16.08 Mn |
| Dec 31, 2020 | -16.08 Mn |
| Sep 30, 2020 | -19.68 Mn |
| Sep 30, 2020 | -19.68 Mn |
| Jun 30, 2020 | -13.99 Mn |
| Jun 30, 2020 | -13.99 Mn |
| Mar 31, 2020 | -3.70 Mn |
| Mar 31, 2020 | -3.70 Mn |
| Dec 31, 2019 | -10.26 Mn |
| Dec 31, 2019 | -10.26 Mn |
| Sep 30, 2019 | -14.99 Mn |
| Sep 30, 2019 | -14.99 Mn |
| Jun 30, 2019 | -16.77 Mn |
| Jun 30, 2019 | -16.77 Mn |
| Mar 31, 2019 | -946,000.00 |
| Mar 31, 2019 | -946,000.00 |
| Dec 31, 2018 | 11.58 Mn |
| Dec 31, 2018 | 11.58 Mn |
| Sep 30, 2018 | -20.24 Mn |
| Sep 30, 2018 | -20.24 Mn |
| Jun 30, 2018 | -27.68 Mn |
| Jun 30, 2018 | -27.68 Mn |
| Mar 31, 2018 | -23.59 Mn |
| Mar 31, 2018 | -23.59 Mn |
| Dec 31, 2017 | -19.77 Mn |
| Dec 31, 2017 | -19.77 Mn |
| Sep 30, 2017 | -17.67 Mn |
| Sep 30, 2017 | -17.67 Mn |
| Jun 30, 2017 | -19.48 Mn |
| Jun 30, 2017 | -19.48 Mn |
| Mar 31, 2017 | -20.80 Mn |
| Mar 31, 2017 | -20.80 Mn |
| Dec 31, 2016 | -12.47 Mn |
| Dec 31, 2016 | -12.47 Mn |
| Sep 30, 2016 | -22.82 Mn |
| Sep 30, 2016 | -22.82 Mn |
| Jun 30, 2016 | -18.66 Mn |
| Jun 30, 2016 | -18.66 Mn |
| Mar 31, 2016 | -22.74 Mn |
| Mar 31, 2016 | -22.74 Mn |
| Dec 31, 2015 | -13.93 Mn |
| Dec 31, 2015 | -13.93 Mn |
| Sep 30, 2015 | -9.76 Mn |
| Sep 30, 2015 | -9.76 Mn |
| Jun 30, 2015 | -18.22 Mn |
| Jun 30, 2015 | -18.22 Mn |
| Mar 31, 2015 | 17.96 Mn |
| Mar 31, 2015 | 17.96 Mn |
| Dec 31, 2014 | -15.20 Mn |
| Dec 31, 2014 | -15.20 Mn |
| Sep 30, 2014 | -18.34 Mn |
| Sep 30, 2014 | -18.34 Mn |
| Jun 30, 2014 | -20.02 Mn |
| Jun 30, 2014 | -20.02 Mn |
| Mar 31, 2014 | -16.61 Mn |
| Mar 31, 2014 | -16.61 Mn |
| Dec 31, 2013 | -19.07 Mn |
| Dec 31, 2013 | -19.07 Mn |
| Sep 30, 2013 | -20.87 Mn |
| Sep 30, 2013 | -20.87 Mn |
| Jun 30, 2013 | -21.57 Mn |
| Jun 30, 2013 | -21.57 Mn |
| Mar 31, 2013 | -25.79 Mn |
| Mar 31, 2013 | -25.79 Mn |
| Dec 31, 2012 | -22.17 Mn |
| Dec 31, 2012 | -22.17 Mn |
| Sep 30, 2012 | -20.01 Mn |
| Sep 30, 2012 | -20.01 Mn |
| Jun 30, 2012 | -21.56 Mn |
| Jun 30, 2012 | -21.56 Mn |
| Mar 31, 2012 | -24.85 Mn |
| Mar 31, 2012 | -24.85 Mn |
| Dec 31, 2011 | -18.84 Mn |
| Dec 31, 2011 | -18.84 Mn |
| Sep 30, 2011 | -13.35 Mn |
| Sep 30, 2011 | -13.35 Mn |
| Jun 30, 2011 | -17.86 Mn |
| Jun 30, 2011 | -17.86 Mn |
| Mar 31, 2011 | -21.62 Mn |
| Mar 31, 2011 | -21.62 Mn |
| Dec 31, 2010 | 9.34 Mn |
| Dec 31, 2010 | 9.34 Mn |
| Sep 30, 2010 | -19.91 Mn |
| Sep 30, 2010 | -19.91 Mn |